Inherited forms of renal cell carcinoma

Scandinavian Journal of Surgery

Volumn 93, Issue 2, 2004, Pages 103-111

  Kiuru, M ^a   Kujala, M ^a,b   Aittomäki, Kristiina ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

FH; Gene; Hereditary; HLRCC; Leiomyomas; MET; Renal cell cancer; VHL

Indexed keywords

CANCER DIAGNOSIS; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLEAR CELL CARCINOMA; CLINICAL PRACTICE; CYTOPATHOLOGY; FAMILIAL CANCER; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; PAPILLARY CARCINOMA; PATHOGENESIS; PATIENT CARE; PROGNOSIS; REVIEW; VHL GENE; VON HIPPEL LINDAU DISEASE;

EID: 3142702050     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690409300204     Document Type: Review

References (63)

1. Ponder BA: Cancer genetics. Nature 2001;411:336-341
2. Marsh DJ, Zori RT: Genetic insights into familial cancer - update and recent discoveries. Cancer Letters 2002;181:125-164
3. Hemminki K, Li X, Czene K: Familial risk of urological cancers: data for clinical counseling. World J Urol 2004;21:377-381
4. Zbar B, Klausner R, Linehan WM: Studying cancer families to identify kidney cancer genes. Annu Rev Med 2003;54:217-233
5. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320
6. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA: Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 2001;98:3387-3392
7. Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lerman M, Linehan WM: Hereditary papillary renal cell carcinoma. J Urol 1994;151:561-566
8. Iliopoulos O, Eng C: Genetic and clinical aspects of familial renal neoplasms. Semin Oncol 2000;27:138-149
9. Lynch HT, Lynch JF: Hereditary nonpolyposis colorectal cancer. Semin Surg Oncol 2000;18:305-313
10. Toro JR, Glenn G, Duray P, Darling T, Weirich G, Zbar B, Linehan M, Turner ML: Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999;135:1195-1202
11. Nickerson M, Warren M, Toro J, Matrosova V, Glenn G, Turner M, Duray P, Merino M, Choyke P, Pavlovich C, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman M, Linehan W, Zbar B, Schmidt L: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002;2:157
12. Bove KE: Wilms' tumor and related abnormalities in the fetus and newborn. Semin Perinatol 1999;23:310-318
13. Maher ER, Iselius L, Yates JR, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N: Von Hippel-Lindau disease: a genetic study. J Med Genet 1991;28:443-447
14. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA: Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163
15. Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ, Whitehouse R, Dodd C, Lavin M, Hartley N, Super M, Evans DG: A genetic register for von Hippel-Lindau disease. J Med Genet 1996;33:120-127
16. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH: Von Hippel-Lindau disease. Lancet 2003;361:2059-2067
17. Linehan MW, Zbar B, Klausner RD: Renal carcinoma. In: The genetic basis of human cancer. Vogelstein B and Kinzler KW. McGraw-Hill, 2002, 499-474
18. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM: Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 1995;154:2010-2014; Discussion 2014-2015
19. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93: 10595-10599
20. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399: 271-275
21. Pause A, Lee S, Lonergan KM, Klausner RD: The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998;95:993-998
22. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968
23. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;30:406-410
24. Kiuru M, Launonen V, Hietala M, Aittomäki K, Vierimaa O, Salovaara R, Arola J, Pukkala E, Sistonen P, Herva R, Aaltonen LA: Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001;159:825-829
25. Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, Choyke P, Stratton P, Merino M, Walther MM, Linehan WM, Schmidt LS, Zbar B: Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003;73:95-106
26. Kiuru M (2002). Molecular basis of hereditary leiomyomatosis and renal cell cancer (HLRCC). Department of Medical Genetics. Helsinki, University of Helsinki: 75
27. Kiuru M, Lehtonen R, Arola J, Salovaara R, Järvinen H, Aittomäki K, Sjöberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, Launonen V, Karhu A, Aaltonen LA: Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002;62:4554-4557
28. Lehtonen R, Kiuru M, Vanharanta S, Sjöberg J, Aaltonen LM, Aittomäki K, Arola J, Butzow R, Eng C, Husgafvel-Pursiainen K, Isola J, Järvinen H, Koivisto P, Mecklin JP, Peltomäki P, Salovaara R, Wasenius VM, Karhu A, Launonen V, Nupponen NN, Aaltonen LA: Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 2004;164:17-22
29. Alam NA, Rowan AJ, Wortham NC, Pollard PJ, Mitchell M, Tyrer JP, Barclay E, Calonje E, Manek S, Adams SJ, Bowers PW, Burrows NP, Charles-Holmes R, Cook LJ, Daly BM, Ford GP, Fuller LC, Hadfield-Jones SE, Hardwick N, Highet AS, Keefe M, MacDonald-Hull SP, Potts ED, Crone M, Wilkinson S, Camacho-Martinez F, Jablonska S, Ratnavel R, MacDonald A, Mann RJ, Grice K, Guillet G, Lewis-Jones MS, McGrath H, Seukeran DC, Morrison PJ, Fleming S, Rahman S, Kelsell D, Leigh I, Olpin S, Tomlinson IP: Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003;12:1241-1252
30. Martinez-Mir A, Glaser B, Chuang GS, Horev L, Waldman A, Engler DE, Gordon D, Spelman LJ, Hatzibougias I, Green DR, Christiano AM, Zlotogorski A: Germline fumarate fydratase mutations in families with multiple cutaneous leiomyomata. J Invest Dermatol 2003;121:741-744
31. Chuang GS, Martinez-Mir A, Horev L, Glaser B, Geyer A, Landau M, Waldman A, Gordon D, Spelman LJ, Hatzibougias I, Engler DE, Cserhalmi-Friedman PB, Green JS, Garcia Muret MP, Prieto Cid M, Brenner S, Sprecher E, Christiano AM, Zlotogorski A: Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. Am J Hum Gen 2003;73:577
32. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA: A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003;3:193-202
33. Barker KT, Bevan S, Wang R, Lu YJ, Flanagan AM, Bridge JA, Fisher C, Finlayson CJ, Shipley J, Houlston RS: Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br J Cancer 2002;87:446-448
34. Zbar B, Glenn G, Lubensky I, Choyke P, Walther MM, Magnusson G, Bergerheim US, Pettersson S, Amin M, Hurley K: Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995;153:907-912
35. Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, Walther MM, Choyke P, Linehan WM, Zbar B: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999;155:517-526
36. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Zbar B et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73
37. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-804
38. Savage DG, Antman KH: Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-693
39. Sampson JR: The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. Nephrol Dial Transplant 1996;11:34-37
40. Sampson JR, Patel A, Mee AD: Multifocal renal cell carcinoma in sibs from a chromosome 9 linked (TSC1) tuberous sclerosis family. J Med Genet 1995;32:848-850
41. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, Lindhout D, van den Ouweland A, Halley D, Young J, Burley M, Jeremiah S, Woodward K, Nahmias J, Fox M, Ekong R, Osborne J, Wolfe J, Povey S, Snell RG, Cheadle JP, Jones AC, Tachataki M, Ravine D, Kwiatkowski DJ et al.: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-808
42. Consortium TECTS: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-1315
43. Takahashi M, Kahnoski R, Gross D, Nicol D, Teh BT: Familial adult renal neoplasia. J Med Genet 2002;39:1-5
44. Haven CJ, Wong FK, van Dam EW, van der Juijt R, van Asperen C, Jansen J, Rosenberg C, de Wit M, Roijers J, Hoppener J, Lips CJ, Larsson C, Teh BT, Morreau H: A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2000;85:1449-1454
45. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H 3rd, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR: HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 2002;32:676-680
46. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS: Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592-595
47. Bodmer D, Eleveld MJ, Ligtenberg MJ, Weterman MA, Janssen BA, Smeets DF, de Wit PE, van den Berg A, van den Berg E, Koolen MI, Geurts van Kessel A: An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet 1998;62:1475-1483
48. Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER: Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 2000;37:348-353
49. Teh BT, Giraud S, Sari NF, Hii SI, Bergerat JP, Larsson C, Limacher JM, Nicol D: Familial non-VHL non-papillary clear-cell renal cancer. Lancet 1997;349:848-849
50. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, Einarsson GV, Jonsdottir GM, Kristjansson K, Hardarson S, Magnusson K, Gulcher J, Stefansson K, Amundadottir LT: A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 2002;100:476-479
51. Schlehofer B, Pommer W, Mellemgaard A, Stewart JH, McCredie M, Niwa S, Lindblad P, Mandel JS, McLaughlin JK, Wahrendorf J: International renal-cell-cancer study. VI. the role of medical and family history. Int J Cancer 1996;66:723-726
52. Dong C, Hemminki K: Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families. Int J Cancer 2001;92:144-150
53. Krejci KG, Blute ML, Cheville JC, Sebo TJ, Lohse CM, Zincke H: Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome. Urology 2003;62:641-646
54. Finnish Cancer Registry: http://www.cancerregistry.fi/
55. Maher ER, Kaelin WG Jr: von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-391
56. Glenn GM, Daniel LN, Choyke P, Linehan WM, Oldfield E, Gorin MB, Hosoe S, Latif F, Weiss G, Walther M et al: Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet 1991;87:207-210
57. VHL Family Alliance. Suggested protocol for screening: http://www.vhl.org
58. Torreggiani WC, Keogh C, Al-Ismail K, Munk PL, Nicolaou S: Von Hippel-Lindau disease: a radiological essay. Clin Radiol 2002;57:670-680
59. Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM: Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 1996;198:785-788
60. Herring JC, Enquist EG, Chernoff A, Linehan WM, Choyke PL, Walther MM: Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001;165:777-781
61. Walther MM, Choyke PL, Glenn G, Lyne JC, Rayford W, Venzon D, Linehan WM: Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 1999;161:1475-1479
62. Walther MM, Choyke PL, Weiss G, Manolatos C, Long J, Reiter R, Alexander RB, Linehan WM: Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 1995;153:913-916
63. Walther MM, Thompson N, Linehan W: Enucleation procedures in patients with multiple hereditary renal tumors. World J Urol 1995;13:248-250